112 related articles for article (PubMed ID: 38875377)
1. NGS panel enhance precise diagnosis of myeloid neoplasms under WHO-HAEM5 and International Consensus Classification: An observational study.
Ye X; Zheng Z; Wu Y; Zhang Z; Xu Z; Liu Y; Jiang L; Wu J
Medicine (Baltimore); 2024 Jun; 103(24):e38556. PubMed ID: 38875377
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
Magaz M; Alvarez-Larrán A; Colomer D; López-Guerra M; García-Criado MÁ; Mezzano G; Belmonte E; Olivas P; Soy G; Cervantes F; Darnell A; Ferrusquía-Acosta J; Baiges A; Turon F; Hernández-Gea V; García-Pagán JC
J Hepatol; 2021 Jan; 74(1):89-95. PubMed ID: 32679300
[TBL] [Abstract][Full Text] [Related]
3. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
5. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
6. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.
Patnaik MM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
Am J Hematol; 2011 May; 86(5):393-8. PubMed ID: 21523797
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1.
Ok CY; Trowell KT; Parker KG; Moser K; Weinberg OK; Rogers HJ; Reichard KK; George TI; Hsi ED; Bueso-Ramos CE; Tam W; Orazi A; Bagg A; Arber DA; Hasserjian RP; Wang SA
Mod Pathol; 2021 Jan; 34(1):20-31. PubMed ID: 32694616
[TBL] [Abstract][Full Text] [Related]
8. A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.
Zhou Q; Zhao D; Zarif M; Davidson MB; Minden MD; Tierens A; Yeung YWT; Wei C; Chang H
Blood Adv; 2024 Apr; 8(7):1760-1771. PubMed ID: 38286462
[TBL] [Abstract][Full Text] [Related]
9. Implications of the 5
Lee C; Kim HN; Kwon JA; Yoon SY; Jeon MJ; Yu ES; Kim DS; Choi CW; Yoon J
Ann Lab Med; 2023 Sep; 43(5):503-507. PubMed ID: 37080752
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
[TBL] [Abstract][Full Text] [Related]
11. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.
Falini B; Martelli MP
Am J Hematol; 2023 Mar; 98(3):481-492. PubMed ID: 36606297
[TBL] [Abstract][Full Text] [Related]
13. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.
Yin CC; Medeiros LJ; Bueso-Ramos CE
Int J Lab Hematol; 2010 Oct; 32(5):461-76. PubMed ID: 20626469
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.
Bhai P; Hsia CC; Schenkel LC; Hedley BD; Levy MA; Kerkhof J; Santos S; Stuart A; Lin H; Broadbent R; Nan S; Yang P; Xenocostas A; Chin-Yee I; Sadikovic B
Mol Diagn Ther; 2022 May; 26(3):333-343. PubMed ID: 35381971
[TBL] [Abstract][Full Text] [Related]
16. Parallel algorithm for myeloproliferative neoplasms testing: the frequency of double mutations is found in the JAK2/MPL genes more often than the JAK2/CALR genes, but is there a clinical benefit?
Gorbenko AS; Stolyar MA; Olkhovskiy IA; Vasiliev EV; Mikhalev MA
Clin Chem Lab Med; 2019 Mar; 57(4):e60-e62. PubMed ID: 30157024
[No Abstract] [Full Text] [Related]
17. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
18. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
19. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
Lin Y; Liu E; Sun Q; Ma J; Li Q; Cao Z; Wang J; Jia Y; Zhang H; Song Z; Ai X; Shi L; Feng X; Li C; Wang J; Ru K
Am J Clin Pathol; 2015 Jul; 144(1):165-71. PubMed ID: 26071474
[TBL] [Abstract][Full Text] [Related]
20. Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification.
Chen X; Yuan L; Zhang Y; Wang F; Ma X; Fang J; Cao P; Liu Y; Liu Z; Liu M; Chen J; Zhou X; Liu M; Jin D; Wang T; Lu P; Liu H
Am J Hematol; 2024 May; 99(5):824-835. PubMed ID: 38321864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
